**Edwards Lifesciences Earnings Conference Call Summary**

**Overview:**
Edwards Lifesciences presented their financial results for the fourth quarter of 2020, reflecting a challenging year due to the COVID-19 pandemic but also highlighting resilience and growth in key areas. The earnings call detailed financial metrics, highlighted product performance, and set the companyâ€™s outlook for 2021.

**Key Financials from Q4 2020:**
- **Total Q4 Sales:** $1.2 billion, consistent with the prior year period despite pandemic pressures.
- **2020 Total Sales:** Rose slightly by 1% to $4.4 billion.
- **Adjusted Earnings Per Share (EPS) for Q4:** Grew by 2% to $0.50.
- **GAAP EPS:** Recorded at $0.49.

**Product Highlights:**
- **Transcatheter Aortic Valve Replacement (TAVR):**
  - Global sales for 2020: $2.9 billion, up by 4%.
  - U.S. TAVR sales in Q4: Stable compared to Q3 but saw a mid-single-digit decline compared to last year.
  - Expected underlying TAVR growth for 2021 is in the 15% to 20% range.

- **Transcatheter Mitral and Tricuspid Therapies (TMTT):**
  - Full Year 2020 sales: $42 million.
  - Achieved approvals for use of Edwards PASCAL Precision System in pivotal studies.
  - Sales projected to approximately double in 2021.

- **Surgical Structural Heart:**
  - Full Year 2020 sales: $762 million, down 10%.
  - Q4 sales: $204 million, decreased 2% year-over-year.
  - Expected full-year 2021 growth in the high single-digit range.

- **Critical Care:**
  - Full Year 2020 sales: $725 million, a decrease of 3%.
  - Q4 sales: $198 million, down 2%.
  - Expected full-year 2021 growth in the high single-digit range.

**Guidance for 2021:**
- **Projected Total Sales:** Between $4.9 billion and $5.3 billion.
- **TAVR Sales Expectations:** Between $3.2 billion and $3.6 billion.
- **TMTT Sales Forecast:** Around $80 million.
- **Surgical Structural Heart Sales:** Projected between $800 million and $900 million.
- **Critical Care Sales Forecast:** Between $725 million and $800 million.
- **Adjusted EPS:** Anticipated to be between $2.00 and $2.20.

**Investments and Innovation:**
- Edwards highlighted ongoing investments in R&D, particularly emphasizing the commitment to TAVR and TMTT development. The company is engaged in enrolling seven clinical trials.

**Impact of COVID-19:**
- Ongoing impacts are expected, particularly influencing the early part of 2021, with improvements anticipated in the latter half of the year.

**Strategic Highlights:**
- Despite the turbulent environment, Edwards focuses on innovation and maintaining leading positions in markets such as TAVR and preparedness for a post-pandemic recovery.
- Strategic investments in infrastructure and human resources aiming to support long-term growth.

**Conclusion:**
Edwards Lifesciences demonstrated resilience amidst a challenging 2020, maintaining focus on innovation and strategic growth. With strong fundamentals and a robust product pipeline, they expect to navigate through 2021 with optimism for recovery and expansion.